Gail S. Kerr

Gail S. Kerr

Auto-generated profile, based on publicly available information

Gail S. Kerr

Washington DC VA Medical Center Washington DC

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
DKDinesh Khanna
Dinesh Khanna
John FitzGeraldJohn FitzGerald
John FitzGerald
PKPuja Khanna
Puja Khanna
SBSangmee Bae
Sangmee Bae
MSManjit K. Singh
Manjit K. Singh
RTRobert Terkeltaub
Robert Terkeltaub
Click on the article title to read more.

28 September 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
DKDinesh Khanna
Dinesh Khanna
PKPuja Khanna
Puja Khanna
John FitzGeraldJohn FitzGerald
John FitzGerald
MSManjit K. Singh
Manjit K. Singh
SBSangmee Bae
Sangmee Bae
RTRobert Terkeltaub
Robert Terkeltaub
Click on the article title to read more.

15 October 2010 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
GKGail S. Kerr
Gail S. Kerr
ISIraj Sabahi
Iraj Sabahi
JRJohn S. Richards
John S. Richards
LCLiron Caplan
Liron Caplan
GCGrant W. Cannon
Grant W. Cannon
TMTed R. Mikuls
Ted R. Mikuls
Objective.: 25-hydroxy-vitamin D (25-OH-D) insufficiency/deficiency is increasingly prevalent and has been associated with many chronic diseases, including rheumatoid arthritis (RA). Our purpose was to define the prevalence and associations of 25-OH-D insufficiency/deficiency in a cohort of US veterans with RA.Methods.: Vitamin D status (25-OH-D) was assessed in patients with RA using radioimmunoassay on banked plasma collected at enrollment. Insufficiency was defined as concentrations < 30 ng/ml and deficiency as < 20 ng/ml. Associations of 25-OH-D insufficiency/deficiency with patient characteristics obtained at enrollment were examined using multivariate logistic regression, adjusting for age, sex, season of enrollment, and race.Results.: Patients (850 men, 76% Caucasian) had a mean (SD) age of 64 (SD 11.3) years. The prevalences of 25-OH-D insufficiency and deficiency were 84% and 43%, respectively. After multivariate adjustment, both insufficiency and deficiency were more common with anti-cyclic citrullinated peptide antibody positivity and non-Caucasian race, and in the absence of vitamin D supplementation. 25-OH-D deficiency, but not insufficiency, was independently associated with higher tender joint counts and highly sensitive C-reactive protein levels.Conclusion.: In a predominantly elderly, male RA population, 25-OH-D insufficiency was highly prevalent. With the increasing adverse health outcomes associated with hypovitaminosis D, screening and supplementation, particularly among minority, seropositive patients with RA, should be performed routinely.

1 April 2014 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
GKGail Kerr
Gail Kerr
MAMireille Aujero
Mireille Aujero
JRJohn Richards
John Richards
HSHarlan Sayles
Harlan Sayles
LDLisa Davis
Lisa Davis
TMTed Mikuls
Ted Mikuls
Objective: To evaluate the association of hydroxychloroquine (HCQ) use with lipid profiles in a Veterans Affairs Rheumatoid Arthritis (VARA) cohort.Methods: Lipid profiles in HCQ users were compared with HCQ nonusers, adjusting for potential confounders (age, sex, race, disease activity, prednisone, disease‐modifying antirheumatic drugs, diabetes mellitus, and statin use). Applying current National Cholesterol Education Program Adult Treatment Panel III (NCEP‐ATP III) guidelines for reduction of cardiovascular disease (CVD) events risk, the frequency of target lipid profiles with HCQ status was evaluated. Varied periods of HCQ exposure were compared to ascertain pharmacologic associations with lipid values. CVDs were compared between HCQ users and nonusers.Results: In an elderly, predominantly male VARA cohort, 1,011 patients had lipid profiles; 787 patients (77.8%) were white. Statin use was recorded in 11.6% of patients, diabetes mellitus in 33.5%, and CVD in 31.2%. HCQ users (n = 150) were older, had longer rheumatoid arthritis (RA) disease duration, and had lower disease activity. Optimum lipid profiles, including total cholesterol:high‐density lipoprotein (HDL) and HDL:low‐density lipoprotein ratios (P ≤ 0.001), were more frequent in HCQ users, with the exception of HDL (P = 0.165), and persisted in multivariate analyses. Similarly, more HCQ users had NCEP‐ATP III target levels. Varied periods of HCQ exposure suggested lipid changes to occur early, but lost within a year of drug discontinuation. HCQ users had less prevalent CVD.Conclusion: In RA patients, HCQ use of at least 3 months' duration was associated with better lipid profiles irrespective of disease activity or statin use. Given the increased CVD risks in RA and the relative low cost and toxicity of HCQ, continued use, regardless of treatment regimen, should be considered.

28 August 2014 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGail S. Kerr
Gail S. Kerr
SQSeema Qaiyumi
Seema Qaiyumi
JRJohn Richards
John Richards
HVHashem Vahabzadeh-Monshie
Hashem Vahabzadeh-Monshie
CKChesahna Kindred
Chesahna Kindred
FCFlorina Constantinescu
Florina Constantinescu

15 November 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AAAsha M. Alex
Asha M. Alex
GKGary Kunkel
Gary Kunkel
HSHarlan Sayles
Harlan Sayles
JAJorge D. Flautero Arcos
Jorge D. Flautero Arcos
TMTed R. Mikuls
Ted R. Mikuls
GKGail S. Kerr
Gail S. Kerr